Stephen Peters

Summary

Affiliation: Wake Forest University School of Medicine
Country: USA

Publications

  1. pmc Asthma and gender impact accumulation of T cell subtypes
    Matthew J Loza
    Department of Internal Medicine, Center for Human Genomics, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Respir Res 11:103. 2010
  2. pmc Alterations in vasodilator-stimulated phosphoprotein (VASP) phosphorylation: associations with asthmatic phenotype, airway inflammation and beta2-agonist use
    Annette T Hastie
    Department of Internal Medicine, Center for Human Genomics, Wake Forest University School of Medicine, Winston Salem, NC, USA
    Respir Res 7:25. 2006
  3. ncbi request reprint Part IV: Genetic variations in beta2-adrenergic receptors: long-acting and short-acting beta2-agonists and therapeutic response
    Stephen Peters
    Center for Human Genomics, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Curr Med Res Opin 23:S29-36. 2007
  4. ncbi request reprint Asthma treatment in the 21st century: what's next?
    Stephen P Peters
    Center for Human Genomics and Department of Medicine, Section on Pulmonary and Critical Care Medicine, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA
    Clin Rev Allergy Immunol 27:197-205. 2004
  5. pmc Reporting and evaluating genetic association studies
    Stephen P Peters
    Wake Forest University Health Sciences, Center for Human Genomics, Winston Salem, NC, USA
    Respir Res 10:109. 2009
  6. pmc Safety of inhaled corticosteroids in the treatment of persistent asthma
    Stephen P Peters
    Wake Forest University Health Sciences, Center for Human Genomics, Winston Salem, NC 27157, USA
    J Natl Med Assoc 98:851-61. 2006
  7. doi request reprint Long-term safety and asthma control with budesonide/formoterol versus budesonide pressurized metered-dose inhaler in asthma patients
    Stephen P Peters
    Section on Pulmonary and Critical Care Medicine, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
    Allergy Asthma Proc 29:499-516. 2008
  8. ncbi request reprint Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment
    Stephen P Peters
    Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157, USA
    Respir Med 100:1139-51. 2006
  9. ncbi request reprint The impact of comorbid atopic disease on asthma: clinical expression and treatment
    Stephen Peters
    Department of Medicine, Section on Pulmonary, Critical Care, Allergy and Immunologic Diseases and the Center for Human Genomics, Wake Forest University School of Medicine, Winston, NC 27157 1052, USA
    J Asthma 44:149-61. 2007
  10. pmc Tiotropium bromide step-up therapy for adults with uncontrolled asthma
    Stephen P Peters
    Wake Forest University Health Sciences, Center for Genomics and Personalized Medicine Research, Medical Center Blvd, Winston Salem, NC 27157, USA
    N Engl J Med 363:1715-26. 2010

Research Grants

  1. ASTHMA CLINICAL RESEARCH NETWORK (ACRN)
    Stephen Peters; Fiscal Year: 2003
  2. CONTROL OF IGE MEDIATED PULMONARY INFLAMMATION IN HUMANS
    Stephen Peters; Fiscal Year: 2001
  3. CONTROL OF IGE MEDIATED PULMONARY INFLAMMATION IN HUMANS
    Stephen Peters; Fiscal Year: 2000
  4. THE MODULATION OF INFLAMMATORY RESPONSES IN THE LUNG
    Stephen Peters; Fiscal Year: 1993
  5. MODULATION OF INFLAMMATORY RESPONSES IN THE LUNG
    Stephen Peters; Fiscal Year: 1992
  6. CONTROL OF IGE MEDIATED PULMONARY INFLAMMATION IN HUMANS
    Stephen Peters; Fiscal Year: 1999
  7. ASTHMA CLINICAL RESEARCH NETWORK (ACRN)
    Stephen Peters; Fiscal Year: 2007

Detail Information

Publications57

  1. pmc Asthma and gender impact accumulation of T cell subtypes
    Matthew J Loza
    Department of Internal Medicine, Center for Human Genomics, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Respir Res 11:103. 2010
    ..We sought to establish whether CD3+CD28-mediated and antigen-independent accumulation of type 1 and type 2 T cells differs significantly between nonasthmatic and asthmatic populations...
  2. pmc Alterations in vasodilator-stimulated phosphoprotein (VASP) phosphorylation: associations with asthmatic phenotype, airway inflammation and beta2-agonist use
    Annette T Hastie
    Department of Internal Medicine, Center for Human Genomics, Wake Forest University School of Medicine, Winston Salem, NC, USA
    Respir Res 7:25. 2006
    ....
  3. ncbi request reprint Part IV: Genetic variations in beta2-adrenergic receptors: long-acting and short-acting beta2-agonists and therapeutic response
    Stephen Peters
    Center for Human Genomics, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Curr Med Res Opin 23:S29-36. 2007
    ..Any patient with asthma who requires adjunctive use of a long-acting beta2-agonist in addition to an inhaled corticosteroid should be carefully monitored for possible adverse asthma outcomes...
  4. ncbi request reprint Asthma treatment in the 21st century: what's next?
    Stephen P Peters
    Center for Human Genomics and Department of Medicine, Section on Pulmonary and Critical Care Medicine, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA
    Clin Rev Allergy Immunol 27:197-205. 2004
    ....
  5. pmc Reporting and evaluating genetic association studies
    Stephen P Peters
    Wake Forest University Health Sciences, Center for Human Genomics, Winston Salem, NC, USA
    Respir Res 10:109. 2009
    ..All of these elements are important in evaluating such studies and should be carefully considered when these studies are conceived and carried out...
  6. pmc Safety of inhaled corticosteroids in the treatment of persistent asthma
    Stephen P Peters
    Wake Forest University Health Sciences, Center for Human Genomics, Winston Salem, NC 27157, USA
    J Natl Med Assoc 98:851-61. 2006
    ..This review discusses the safety of ICSs with respect to potential systemic effects of most concern to physicians and patients...
  7. doi request reprint Long-term safety and asthma control with budesonide/formoterol versus budesonide pressurized metered-dose inhaler in asthma patients
    Stephen P Peters
    Section on Pulmonary and Critical Care Medicine, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
    Allergy Asthma Proc 29:499-516. 2008
    ..Improvements in asthma control were shown with both doses of budesonide/formoterol versus budesonide...
  8. ncbi request reprint Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment
    Stephen P Peters
    Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157, USA
    Respir Med 100:1139-51. 2006
    ..Comparative trials are needed to determine the merits of different treatments and strategies for patients with inadequately controlled severe persistent asthma and to identify patients likely to benefit from new treatment options...
  9. ncbi request reprint The impact of comorbid atopic disease on asthma: clinical expression and treatment
    Stephen Peters
    Department of Medicine, Section on Pulmonary, Critical Care, Allergy and Immunologic Diseases and the Center for Human Genomics, Wake Forest University School of Medicine, Winston, NC 27157 1052, USA
    J Asthma 44:149-61. 2007
    ..IgE blockade, leukotriene modulation, and B-cell depletion therapy have all exhibited success in chronic inflammation, reinforcing and expanding the beneficial role of immunomodulation of global mediators...
  10. pmc Tiotropium bromide step-up therapy for adults with uncontrolled asthma
    Stephen P Peters
    Wake Forest University Health Sciences, Center for Genomics and Personalized Medicine Research, Medical Center Blvd, Winston Salem, NC 27157, USA
    N Engl J Med 363:1715-26. 2010
    ..Long-acting beta-agonist (LABA) therapy improves symptoms in patients whose asthma is poorly controlled by an inhaled glucocorticoid alone. Alternative treatments for adults with uncontrolled asthma are needed...
  11. ncbi request reprint Hydrofluoroalkane mandate in effect January 1, 2009: Switch from chlorofluorocarbon- to hydrofluoroalkane-propelled inhalers requires active transition
    Stephen Peters
    Section on Pulmonary and Critical Care Medicine, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
    Clin Cornerstone 9:50-3. 2009
    ..Clinicians should actively transition patients to currently available hydrofluoroalkane-propelled devices, providing concise education and instruction for using the newer devices...
  12. doi request reprint Pharmacogenetics of asthma
    Gregory A Hawkins
    Section on Pulmonary, Critical Care, Allergy and Immunologic Diseases, Center for Human Genomics, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA
    Methods Mol Biol 448:359-78. 2008
    ....
  13. ncbi request reprint Randomized comparison of strategies for reducing treatment in mild persistent asthma
    Stephen P Peters
    Wake Forest University, Winston Salem, NC, USA
    N Engl J Med 356:2027-39. 2007
    ....
  14. pmc Safety of investigative bronchoscopy in the Severe Asthma Research Program
    Wendy C Moore
    Center for Human Genomics and Personalized Medicine Research, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    J Allergy Clin Immunol 128:328-336.e3. 2011
    ..We evaluated the safety aspects of this procedure in this cohort with specific focus on patients with severe asthma...
  15. pmc Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program
    Wendy C Moore
    Center for Human Genomics, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157, USA
    Am J Respir Crit Care Med 181:315-23. 2010
    ..The Severe Asthma Research Program cohort includes subjects with persistent asthma who have undergone detailed phenotypic characterization. Previous univariate methods compared features of mild, moderate, and severe asthma...
  16. pmc Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma case-control study
    Gregory A Hawkins
    Center for Human Genomics, Wake Forest University Health Sciences, Winston Salem, NC 27157, USA
    Am J Respir Crit Care Med 174:1101-9. 2006
    ....
  17. ncbi request reprint Long-acting beta agonists in asthma therapy
    Richard W Rissmiller
    Wake Forest University School of Medicine, Center for Human Genomics, Medical Center Boulevard, Winston Salem, NC 27157, USA
    Curr Allergy Asthma Rep 4:91-2. 2004
  18. ncbi request reprint Interactive effects of steroids and beta-agonists on accumulation of type 2 T cells
    Matthew J Loza
    Department of Internal Medicine, Center for Human Genomics, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    J Allergy Clin Immunol 121:750.e1-5.e3. 2008
    ....
  19. ncbi request reprint Severe asthma: an overview
    Wendy C Moore
    Center for Human Genomics, and Department of Internal Medicine, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    J Allergy Clin Immunol 117:487-94; quiz 495. 2006
    ..Treatment algorithms based on markers of airway inflammation may decrease measures of health care utilization in severe asthma...
  20. ncbi request reprint Update in asthma 2006
    Wendy C Moore
    Center for Human Genomics and Department of Internal Medicine, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157, USA
    Am J Respir Crit Care Med 175:649-54. 2007
  21. ncbi request reprint Neutrophils in asthma
    Ana L MacDowell
    Department of Internal Medicine, Section of Pulmonary, Critical Care, Allergy, and Immunological Diseases, Wake Forest University, Medical Center Boulevard, Winston Salem, NC 27157, USA
    Curr Allergy Asthma Rep 7:464-8. 2007
    ..Increasing evidence suggest that neutrophils may be central players with an important role in the pulmonary inflammatory process present in asthma...
  22. doi request reprint The irreversible component of persistent asthma
    Rodolfo M Pascual
    Department of Internal Medicine, Section on Pulmonary, Wake Forest University School of Medicine, Center for Human Genomics, Winston Salem, NC 27157, USA
    J Allergy Clin Immunol 124:883-90; quiz 891-2. 2009
    ..Herein, the evidence of an irreversible component of asthma, its underlying pathology, and the limitations of current asthma treatments are reviewed...
  23. doi request reprint Beta-2 adrenergic agonists: focus on safety and benefits versus risks
    Victor E Ortega
    Wake Forest University Health Sciences, Center for Genomics and Personalized Medicine Research, Medical Center Boulevard, Winston Salem, NC, United States
    Curr Opin Pharmacol 10:246-53. 2010
    ....
  24. pmc Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes
    Annette T Hastie
    Center for Human Genomics, Wake Forest University Health Sciences, Winston Salem, NC 27157, USA
    J Allergy Clin Immunol 125:1028-1036.e13. 2010
    ..Patients with severe asthma have increased granulocytes in their sputum compared with patients with mild to moderate asthma...
  25. doi request reprint The glucocorticoid receptor heterocomplex gene STIP1 is associated with improved lung function in asthmatic subjects treated with inhaled corticosteroids
    Gregory A Hawkins
    Section on Pulmonary, Critical Care, Allergy and Immunologic Diseases, Center for Human Genomics, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    J Allergy Clin Immunol 123:1376-83.e7. 2009
    ..Corticosteroids exert their anti-inflammatory action by binding and activating the intracellular glucocorticoid receptor heterocomplex...
  26. pmc Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program
    Wendy C Moore
    Center for Human Genomics, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    J Allergy Clin Immunol 119:405-13. 2007
    ..Severe asthma causes the majority of asthma morbidity. Understanding mechanisms that contribute to the development of severe disease is important...
  27. ncbi request reprint Airway remodeling contributes to the progressive loss of lung function in asthma: an overview
    Rodolfo M Pascual
    Center for Human Genomics and the Department of Internal Medicine, Section on Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    J Allergy Clin Immunol 116:477-86; quiz 487. 2005
    ..However, clinical studies to date have been disappointing, and it remains to be seen whether targeted therapies will prevent the progressive loss of lung function seen in asthma...
  28. pmc Pharmacogenetics of the beta 2-adrenergic receptor gene
    Victor E Ortega
    Center for Human Genomics, Section of Pulmonary, Critical Care, Allergy, and Immunologic Diseases, Department of Internal Medicine, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Immunol Allergy Clin North Am 27:665-84; vii. 2007
    ..Meanwhile, the conflicting data concerning LABAs may be caused by such factors as small sample sizes of study populations and differences in experimental design...
  29. pmc Genome-wide association study of asthma identifies RAD50-IL13 and HLA-DR/DQ regions
    Xingnan Li
    Center for Human Genomics, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    J Allergy Clin Immunol 125:328-335.e11. 2010
    ..Genome-wide association studies (GWASs) represent a powerful approach to investigate the association of DNA variants with disease susceptibility. To date, few GWASs for asthma have been reported...
  30. ncbi request reprint Novel and emerging therapies for asthma
    Thomas M Leath
    Department of Medicine, Section on Pulmonary, Critical Care, Allergy and Immunological Diseases, Center for Human Genomics, Wake Forest University School of Medicine, Winston Salem, NC, USA
    Drug Discov Today 10:1647-55. 2005
    ..Finally, we will discuss the recently approved anti-IgE therapy for the treatment of allergic asthma and immune modulation using CpG oligodeoxynucleotides...
  31. ncbi request reprint Regulation of phospholipase A2 by interleulin-1 in human airway smooth muscle
    Rudolfo M Pascual
    Department of Medicine, Jefferson Medical College, and Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Chest 123:433S-4S. 2003
  32. ncbi request reprint beta-Agonist enhances type 2 T-cell survival and accumulation
    Matthew J Loza
    Department of Internal Medicine, Center for Human Genomics, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    J Allergy Clin Immunol 119:235-44. 2007
    ..beta-Adrenergic receptor ligands (beta-agonists) subserve numerous physiologic processes but also function as pathogenic or therapeutic agents in numerous diseases with inflammatory components...
  33. ncbi request reprint Real-world Evaluation of Asthma Control and Treatment (REACT): findings from a national Web-based survey
    Stephen P Peters
    Center for Human Genomics and Department of Internal Medicine, Section on Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    J Allergy Clin Immunol 119:1454-61. 2007
    ..However, the prevalence of uncontrolled asthma in the United States is not known and has not been fully characterized...
  34. pmc Beta-agonists modulate T-cell functions via direct actions on type 1 and type 2 cells
    Matthew J Loza
    Department of Internal Medicine, Center for Human Genomics, Wake Forest University School of Medicine, Medical Center Blvd, Winston Salem, NC 27157, USA
    Blood 107:2052-60. 2006
    ..These findings identify direct effects of beta2AR activation on T-cell subtypes and suggest a complex role for GPCRs and PKA activity in modulating T-cell functions...
  35. ncbi request reprint Regulatory features of interleukin-1beta-mediated prostaglandin E2 synthesis in airway smooth muscle
    Rodolfo M Pascual
    Department of Internal Medicine and Center for Human Genomics, Wake Forest Univ Health Sciences Center, Center for Human Genomics, Medical Center Blvd, Winston Salem, NC 27157, USA
    Am J Physiol Lung Cell Mol Physiol 290:L501-8. 2006
    ..mPGES induction and, possibly, cPLA2 induction appear to cooperate with COX-2 to determine IL-1beta-mediated PGE2 production in human ASM cells...
  36. pmc The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial
    Richard J Martin
    National Jewish Medical and Research Center, Denver, CO 80206, USA
    J Allergy Clin Immunol 119:73-80. 2007
    ..Although guidelines recommend anti-inflammatory therapy for persistent asthma, recent studies suggest that 25% to 35% of patients with asthma may not improve lung function with inhaled corticosteroids...
  37. ncbi request reprint Leukotriene receptor antagonists in asthma therapy
    Stephen P Peters
    Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA
    J Allergy Clin Immunol 111:S62-70. 2003
    ....
  38. ncbi request reprint Modulation of vasodilator-stimulated phosphoprotein in vivo in human epithelial cells by segmental allergen challenge and beta2-agonist therapy
    Annette T Hastie
    Thomas Jefferson University, Philadelphia, PA 19107, USA
    Chest 123:377S. 2003
  39. ncbi request reprint Allergic rhinitis, asthma, airway biology, and chronic obstructive pulmonary disease in AJRCCM in 2004
    Leonardo Fabbri
    Medical, Oncological, and Radiological Sciences, University of Modena, Modena, Italy
    Am J Respir Crit Care Med 171:686-98. 2005
  40. ncbi request reprint Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial
    Elliot Israel
    Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Lancet 364:1505-12. 2004
    ..However, the existence of any genotype-dependent difference has not been tested in a prospective clinical trial...
  41. ncbi request reprint Asthma exacerbations and formoterol
    Richard W Rissmiller
    Chest 125:1590-1. 2004
  42. ncbi request reprint Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids
    Aaron Deykin
    Brigham and Women s Hospital and Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    J Allergy Clin Immunol 115:720-7. 2005
    ..Although inhaled corticosteroids (ICSs) are effective in preventing deterioration in asthma control, at least half of subjects with mild-to-moderate asthma will remain stable when these agents are discontinued...
  43. pmc ARG1 is a novel bronchodilator response gene: screening and replication in four asthma cohorts
    Augusto A Litonjua
    Channing Laboratory, Pulmonary Division, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Respir Crit Care Med 178:688-94. 2008
    ..However, a substantial proportion of patients with asthma do not have a favorable response to these drugs, and identifying genetic determinants of drug response may aid in tailoring treatment for individual patients...
  44. ncbi request reprint Daily versus as-needed corticosteroids for mild persistent asthma
    Homer A Boushey
    University of California at San Francisco, San Francisco, USA
    N Engl J Med 352:1519-28. 2005
    ....
  45. ncbi request reprint Systemic effect comparisons of six inhaled corticosteroid preparations
    Richard J Martin
    National Jewish Medical and Research Center, Denver, Colorado 80206, USA
    Am J Respir Crit Care Med 165:1377-83. 2002
    ..This study represents the first step in evaluation of ICS efficacy based on equisystemic (cortisol suppression) effects of a given ICS, rather than doses judged arbitrarily to be comparable on a microgram basis...
  46. ncbi request reprint Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation
    Ronald L Sorkness
    Univ of Wisconsin, 777 Highland Ave, Madison, WI 53705, USA
    J Appl Physiol (1985) 104:394-403. 2008
    ..We conclude that air trapping is a characteristic feature of the severe asthma population, suggesting that there is a pathological process associated with severe asthma that makes airways more vulnerable to this component...
  47. pmc beta-Adrenergic receptor polymorphisms and response to salmeterol
    Michael E Wechsler
    Brigham and Women s Hospital, 75 Francis Street, Boston, MA, 02115, USA
    Am J Respir Crit Care Med 173:519-26. 2006
    ..Several studies suggest that patients with asthma who are homozygous for arginine at the 16th position of the beta2-adrenergic receptor may not benefit from short-acting beta-agonists...
  48. pmc Combination therapy with a long-acting beta-agonist and a leukotriene antagonist in moderate asthma
    Aaron Deykin
    Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Respir Crit Care Med 175:228-34. 2007
    ..The elements of asthma control achieved by LABAs (improved lung function) and leukotriene receptor antagonists (LTRAs; protection against exacerbations) may be complementary as well...
  49. ncbi request reprint Asthma end points and outcomes: what have we learned?
    Don Bukstein
    Allergy and Asthma Research, Dean Medical Center, Department of Pediatrics and Family Practice, University of Wisconsin Medical School, Madison, Wisconsin, USA
    J Allergy Clin Immunol 118:S1-15. 2006
    ..The fraction of exhaled nitric oxide as a measure of inflammation is suggested as offering the best combination of disease evaluation and practical implementation for improved asthma outcomes...
  50. ncbi request reprint Significant variability in response to inhaled corticosteroids for persistent asthma
    Stanley J Szefler
    National Jewish Medical and Research Center, Department of Pediatrics, Denver, CO 80206, USA
    J Allergy Clin Immunol 109:410-8. 2002
    ..A clinical model is needed to compare inhaled corticosteroids (ICSs) with respect to efficacy...
  51. ncbi request reprint Concentration of cytokines and growth factors in BAL fluid after allergen challenge in asthmatics and their effect on alpha-smooth muscle actin and collagen III synthesis by human lung fibroblasts
    Vikas Batra
    Thomas Jefferson University, Philadelphia, PA, USA
    Chest 123:398S-9S. 2003
  52. ncbi request reprint Heterogeneity in the pathology and treatment of asthma
    Stephen P Peters
    Jefferson Medical College, Pulmonary Division, Philadelphia, Pennsylvania, USA
    Am J Med 115:49S-54S. 2003
    ..Understanding the causes of asthma heterogeneity and their implications for asthma treatment is a major challenge for the new millennium...
  53. ncbi request reprint Asthmatic epithelial cell proliferation and stimulation of collagen production: human asthmatic epithelial cells stimulate collagen type III production by human lung myofibroblasts after segmental allergen challenge
    Annette T Hastie
    Department of Medicine, Division of Critical Care, Pulmonary, Allergic and Immunologic Diseases, and Division of Clinical Pharmacology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania
    Am J Respir Crit Care Med 165:266-72. 2002
    ..Epithelial cell proliferation appears dependent upon infiltrating inflammatory cells, but stimulation of collagen type III does not...
  54. pmc Alterations of the arginine metabolome in asthma
    Abigail Lara
    Department of Pathobiology, The Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Am J Respir Crit Care Med 178:673-81. 2008
    ..As the sole nitrogen donor in nitric oxide (NO) synthesis and key intermediate in the urea cycle, arginine and its metabolic pathways are integrally linked to cellular respiration, metabolism, and inflammation...
  55. pmc Investigative bronchoprovocation and bronchoscopy in airway diseases
    William W Busse
    University of Wisconsin Madison, USA
    Am J Respir Crit Care Med 172:807-16. 2005
    ..Since the last critical review more than a decade ago, some of the techniques and applications have changed, and untoward events have occurred, raising safety concerns and increasing institutional review scrutiny...
  56. pmc Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma
    Stephen C Lazarus
    University of California, San Francisco, 505 Parnassus Avenue, M 1083, San Francisco, CA 94143 0111, USA
    Am J Respir Crit Care Med 175:783-90. 2007
    ..One-quarter to one-third of individuals with asthma smoke, which may affect response to therapy and contribute to poor asthma control...
  57. ncbi request reprint Distinction between IL-13+ and IFN-gamma+ natural killer cells and regulation of their pool size by IL-4
    Matthew J Loza
    Department of Microbiology and Immunology, Kimmel Cancer Center, Jefferson Medical College, 233 S 10th Street, Philadelphia, PA 19107, USA
    Eur J Immunol 32:413-23. 2002
    ..These data define the existence and regulation of two distinct resting peripheral NK cell subsets producing type 1 and type 2 cytokines, and suggest possible roles for IL-13+ NK cells in allergy...

Research Grants13

  1. ASTHMA CLINICAL RESEARCH NETWORK (ACRN)
    Stephen Peters; Fiscal Year: 2003
    ....
  2. CONTROL OF IGE MEDIATED PULMONARY INFLAMMATION IN HUMANS
    Stephen Peters; Fiscal Year: 2001
    ....
  3. CONTROL OF IGE MEDIATED PULMONARY INFLAMMATION IN HUMANS
    Stephen Peters; Fiscal Year: 2000
    ....
  4. THE MODULATION OF INFLAMMATORY RESPONSES IN THE LUNG
    Stephen Peters; Fiscal Year: 1993
    ..In addition, they will provide crucial information needed in order to develop novel strategies for the treatment of asthma using antiinflammatory agents...
  5. MODULATION OF INFLAMMATORY RESPONSES IN THE LUNG
    Stephen Peters; Fiscal Year: 1992
    ..In addition, they will provide crucial information needed in order to develop novel strategies for the treatment of asthma using antiinflammatory agents...
  6. CONTROL OF IGE MEDIATED PULMONARY INFLAMMATION IN HUMANS
    Stephen Peters; Fiscal Year: 1999
    ....
  7. ASTHMA CLINICAL RESEARCH NETWORK (ACRN)
    Stephen Peters; Fiscal Year: 2007
    ....